Send to

Choose Destination
Am J Obstet Gynecol. 1980 May 1;137(1):92-101.

Estrogen and endometrial cancer: cases and two control groups from North Carolina.



The relationship between exogenous estrogen and risk of endometrial carcinoma was investigated in 256 women with pathologically confirmed cases, 224 gynecology controls, and 321 community controls. Sources of data included personal interviews, physicians' records, and hospital records; diagnoses were verified by 2 outside pathologists. Black women revealed no difference in estrogen use between the cases and both sets of controls, while white women revealed risk of 3.6 and 4.1 after 3 1/2 years of estrogen use. Shorter duration of use, irrespective of dose or type of estrogen, did not increase risk. There was no increased risk in obese women, who prosumably produce increased amounts of exogenous estrogen. The highest risk was found after 3 1/2 years or more of use in nonobese, nonhypertensive women. It was also demonstrated that there is a latency period of 3-6 years after first administration, and that an estrogen-free interval of 2 years is sufficient to reduce elevated risks to nonuser level. Risks of cancer were high for Stage 1A and Grade 1 lesions with estrogen use of long duration.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center